Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026

International Journal of Drug Policy

Volumn 22, Issue 1, 2011, Pages 70-76

  Werb, Daniel ^a   Wood, Evan ^a   Kerr, Thomas ^a,b   Hershfield, Neil ^c   Palmer, Robert W H ^c   Remis, Robert S ^c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Canada; Costs; Hepatitis C; Injection drug use; Treatment

Indexed keywords

ARTICLE; BIRTH; CANADA; CONTROLLED STUDY; COST OF ILLNESS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG ABUSE; HEALTH CARE COST; HEPATITIS C; HIDDEN MARKOV MODEL; HIGH RISK BEHAVIOR; HUMAN; IMMIGRATION; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICAL FEE; POPULATION EXPOSURE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; SEROCONVERSION; VIRUS TRANSMISSION;

CANADA; DRUG USERS; FEMALE; HEALTH CARE COSTS; HEPATITIS C; HIV INFECTIONS; HUMANS; INJECTIONS; MALE; MARKOV CHAINS; RISK; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 79151476346     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2010.09.006     Document Type: Article

References (78)

1. Albert T., Williams G., Remis R., Legowski B. The economic burden of HIV/AIDS in Canada 1998, Canadian Policy Research Network, Toronto.
2. Alter H.J., Conry-Cantilena C., Melpolder J., et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997, 26(3 Suppl. 1):29S-33S.
3. Anand C.M., Fonseca K., Walle R.P., Powell S., Williams M. Antibody to hepatitis C virus in selected groups of a Canadian urban population. International Journal of Epidemiology 1992, 21(1):142-145.
4. Backmund M., Reimer J., Meyer K., Gerlach J.T., Zachoval R. Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment. Clinical Infectious Diseases 2005, 40(Suppl. 5):330-335.
5. Baewert, A., Ebner, N., Thau, K., & Fischer, G. (2005). Treatment of hepatitis C/subtype 2 or 3 with pegylated interferon in combination with ribavirin in a population of opioid-dependent patients [abstract 35]. Program and abstracts of the 67th annual scientific meeting of the College on problems of drug dependence (Orlando, FL) (p. 9). College on Problems of Drug Dependence; Philadelphia.
6. Brown K., Crofts N. Health care costs of a continuing epidemic of hepatitis C virus infection among injecting drug users. Australian and New Zealand Journal of Public Health 1998, 22(3 Suppl.):384-388.
7. Buster M.C.A., Witteveen E., Prins M., van Ameijden E.J.C., Schippers G., Krol A. Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study. European Addiction Research 2009, 15:179-187.
8. Canadian Institute for Health Information Standards for management information systems in Canadian Health Service Organizations 2007, Vol. 2006. Canadian Institute for Health Information, Ottawa.
9. Canadian Institute for Health Research Canadian classification of health interventions 2007, Vol. 2007. Canadian Institute for Health Research, Ottawa.
10. CBC News (2006). Tainted blood scandal. Toronto: CBC. Retrieved from: http://www.cbc.ca/news/background/taintedblood/index.html.
11. Chaudhary R.K., Mo T. Antibody to hepatitis C virus in risk groups in Canada. Canada Diseases Weekly Report 1990, 16(5):23-25.
12. Chaudhary R.K., Rossier E. Prevalence of hepatitis C virus antibodies in renal transplant patients. Canada Diseases Weekly Report 1991, 17(10):53-54.
13. Conway B., Grebely J., Tossonian H., Lefebvre D., de Vlaming S. A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: A Canadian perspective. Clinical Infectious Diseases 2005, 41(Suppl. 1):73-78.
14. Craib K.J.P., Spittal P., Patel S.H., et al. Prevalence and incidence of hepatitis C virus infection among Aboriginal young people who use drugs: results from the Cedar Project. Open Medicine 2009, 3:220.
15. Davis G.L., Alter M.J., El-Serag H., Poynard T., Jennings L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138(2):513-521.
16. Delage G., Infante-Rivard C., Chiavetta J.A., Willems B., Pi D., Fast M. Risk factors for acquisition of hepatitis C virus infection in blood donors: Results of a case-control study. Gastroenterology 1999, 116(4):893-899.
17. Department of Justice Conditional sentencing reform bill (backgrounder) 2006, Department of Justice, Ottawa.
18. Edlin B.R., Seal K.H., Lorvick J., et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users?. New England Journal of Medicine 2001, 345(3):211-215.
19. El Saadany S., Coyle D., Giulivi A., Afal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. European Journal of Health Economics 2005, 6(2):159-165.
20. Ford P.M., White C., Kaufmann H., et al. Seroprevalence of hepatitis C in a Canadian federal penitentiary for women. Canada Communicable Disease Report 1995, 21(14):132-134.
21. Ford P.M., White C., Kaufmann H., et al. Voluntary anonymous linked study of the prevalence of HIV infection and hepatitis C among inmates in a Canadian federal penitentiary for women. Canadian Medical Association Journal 1995, 153(11):1605-1609.
22. Ford P.M., Pearson M., Sankar-Mistry P., Stevenson T., Bell D., Austin J. HIV, hepatitis C and risk behaviour in a Canadian medium-security federal penitentiary. Queen's University HIV Prison Study Group. Monthly Journal of the Association of Physicians 2000, 93(2):113-119.
23. Freeman A.J., Dore G.J., Law M.G., et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34(4 Pt 1):809-816.
24. Geduld J., Gatali M., Remis R.S. Estimates of HIV prevalence and incidence in Canada, 2002 2003, Health Canada, Ottawa.
25. Grebely J., Conway B., Raffa J.D., Lai C., Krajden M., Tyndall M.W. Hepatitis C virus reinfection in injection drug users. Hepatology 2006, 44:1139-1145.
26. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Substance Use and Misuse 1998, 33(5):1197-1212.
27. Heintges T., Wands J.R. Hepatitis C virus: Epidemiology and transmission. Hepatology 1997, 26(3):521-526.
28. Hutchinson S.J., Bird S.M., Goldberg D.J. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005, 42(3):711-723.
29. Hyams K.C., Riddle J., Rubertone M., et al. Prevalence and incidence of hepatitis C virus infection in the US military: A seroepidemiologic survey of 21,000 troops. American Journal of Epidemiology 2001, 153(8):764-770.
30. Jaeckel E., Cornberg M., Wedemeyer H., Santantonio T., Mayer J., Zankel M., Pastore G., Dietrich M., Trautwein C., Manns M.P. Treatment of acute hepatitis C with interferon alfa-2b. New England Journal of Medicine 2001, 345(20):1452-1457. German Acute Hepatitis C Therapy Group.
31. Kim C., Kerr T., Li K., et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009, 9:270.
32. Lamothe, F., Vincelette, J., Bruneau, J., et al. (1997). Prevalence, seroconversion rates and risk factors for hepatitis B core, hepatitis C and HIV antibodies among intravenous drug users (IDU) of the Saint-Luc Cohort (Abstract 221). Sixth annual Canadian conference on HIV/AIDS research.
33. Liddle C. Hepatitis C. Anaesthesia and Intensive Care 1996, 24(2):180-183.
34. Lior L.Y., Beal J., Portman J., et al. A look behind closed doors: Injection and sexual risk behaviour and HIV, HBV, and HVC inside a Canadian prison. International Conference on AIDS 1998, 12:447.
35. Lior, L. Y., Stratton, E., & Archibald, C. P. (1998b). Eastern region project: Seroprevalence of HIV, HBV, and HCV viruses and high risk behaviours among IDU and sexual partners of IDU. [Slide presentation], Report prepared for the Nova Scotia Department of Health.
36. Manuel D.G., Johnson I., Fearon M., Hockin J. The prevalence of hepatitis C in a community-based population, Ontario, 1996. Canada Communicable Disease Report 1999, 25(23):193-199.
37. Mather D., Crofts N. A computer model of the spread of hepatitis C virus among injecting drug users. European Journal of Epidemiology 1999, 15(1):5-10.
38. Mauss S., Berger F., Goelz J., Jacob B., Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004, 40(1):120-124.
39. Medical Research Council of Canada Identification of a research agenda for the diagnosis, care and prevention of hepatitis C in Canada 1999, Medical Research Council of Canada, Ottawa.
40. Miller C.L., Johnston C., Spittal P.M., et al. Opportunities for prevention: Hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002, 36(3):737742.
41. Moses S., Mestery K., Kaita K.D., Minuk G.Y. Viral hepatitis in a Canadian street-involved population. Canadian Journal of Public Health 2002, 93(2):123-128.
42. Muir A.J. The natural history of hepatitis C viral infection. Seminars in Gastrointestinal Disease 2000, 11(2):54-61.
43. Neaigus A., Gyarmathy V.A., Miller M., Frajzyngier V.M., Friedman S.R., Des Jarlais D.C. Transitions to injecting drug use among noninjecting heroin users: social network influence and individual susceptibility. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 2006, 41:493.
44. Ontario Ministry of Health and Long-Term Care Ontario guide to case costing 2006, Government of Ontario, Toronto.
45. Ontario Ministry of Health and Long-Term Care (OMHLTC) Ontario case costing initiative 2007, Government of Ontario, Toronto.
46. Patrick D.M., Tyndall M.W., Cornelisse P.G., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. Canadian Medical Association Journal 2001, 165(7):889-895.
47. Pearson M., Mistry P.S., Ford P.M. Voluntary screening for hepatitis C in a Canadian federal penitentiary for men. Canada Communicable Disease Report 1995, 21(14):134-136.
48. Pohani G., Zou S., Tepper M. Trends of hepatitis B and hepatitis C mortality in Canada, 1979-1997. Canadian Journal of Public Health 2001, 92(4):250-254.
49. Prefontaine R.G., Chaudhary R.K. Seroepidemiologic study of hepatitis B and C viruses in federal correctional institutions in British Columbia. Canada Diseases Weekly Report 1990, 16(52):265-266.
50. Remis, R. (2001). Epidemiology of hepatitis C infection in Canada. Paper presented at 1st Canadian conference on hepatitis C.
51. Remis R. A study to characterize the epidemiology of hepatitis C in Canada, 2002 2003, Health Canada, Ottawa.
52. Remis R.S., Hogg R.S., Krahn M.D., Preiksaitis J.K., Sherman M. Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-85 and 1990-92 1998, Health Canada, Ottawa.
53. Remis R.S., Strathdee S.A., Millson M., et al. Consortium to characterize injection drug users in Montreal, Toronto and Vancouver, Canada 1998, Bureau of HIV/AIDS, STD and TB, Health Canada, Ottawa.
54. Robaeys G., Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastro-enterologica Belgica 2005, 68(1):55-67.
55. Roy E., Haley N., Leclerc P., Boivin J.F., Cedras L., Vincelette J. Risk factors for hepatitis C virus infection among street youths. Canadian Medical Association Journal 2001, 165(5):557-560.
56. Roy E., Haley N., Leclerc P., Cedras L., Blais L., Boivin J.F. Drug injction among street youths in Montreal: Predictors of initiation. Journal of Urban Health 2003, 80(1):92.
57. Roy E., Alary M., Morissette C., et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. International Journal of Std & Aids 2007, 18:23.
58. Salomon J.A., Weinstein M.C., Hammitt J.K., Goldie S.J. Empirically calibrated model of hepatitis C virus infection in the United States. American Journal of Epidemiology 2002, 156(8):761-773.
59. Schreiber G.B., Busch M.P., Kleinman S.H., Korelitz J.J. The risk of transfusion-transmitted viral infections. The New England Journal of Medicine 1996, 334(26):1685-1690.
60. Seeff L.B. Natural history of chronic hepatitis C. Hepatology 2002, 36(Suppl. 1):S35-S46.
61. Seeff L.B., Hollinger F.B., Alter H.J., et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National heart, Lung, and Blood Institute collaborative study. Hepatology 2001, 33(2):455-463.
62. Shannon K., Kerr T., Marshall B., et al. Survival sex work involvement as a primary risk factor for hepatitis C virus acquisition in drug-using youths in a canadian setting. Archives of Pediatrics and Adolescent Medicine 2010, 164:61.
63. Sherman M., Bain V., Villeneuve J.P., Myers R.P., Cooper C., Martin S., Lowe C. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Canadian Journal of Gastroenterology 2004, 18(12):715-728.
64. Single E. A socio-demographic profile of drug users in Canada 2000, Health Canada, Ottawa.
65. Siushansian, J., Vooght, M., Hudson, S., Bangura, H., Archibald, C.P., & Young, E. (2001). The Prince Albert Seroprevalence Study (PASS): Prevalence of HIV, hepatitis B, and hepatitis C and high-risk sexual behaviours among injection drug users and their sexual partners. Ottawa: Division of HIV/AIDS Epidemiology and Surveillance, Centre for Infectious Disease Prevention and Control; Prince Albert Health District and Saskatchewan Health.
66. Statistics Canada (2006). Projected population by age group and sex according to a medium growth scenario for 2006, 2011, 2016, 2021, 2026 and 2031, at July 1, 2006. Ottawa: Statistics Canada.
67. Strathdee S.A., Patrick D.M., Currie S.L., et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 1997, 11(8):F59-65.
68. Torgerson D.J., Raftery J. Economic notes: Discounting. BMJ 1999, 319(7214):914-915.
69. van Ameijden E.J., van den Hoek J.A., Hartgers C., Coutinho R.A. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. American Journal of Epidemiology 1994, 139:1153.
70. Van Thiel D.H., Anantharaju A., Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug use. American Journal of Gastroenterology 2003, 98(10):2281-2288.
71. Wiebe, J. (2000). Profile of hepatitis C and injection drug use in Canada. Ottawa: Hepatitis C Division, Centre for Infectious Disease Prevention and Control, Health Canada.
72. Wong J.B. Hepatitis C: Cost of illness and considerations for the economic evaluation of antiviral therapies. PharmacoEconomics 2006, 24(7):661-672.
73. Wong J.B., McQuillan G.M., McHutchison J.G., Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. American Journal of Public Health 2001, 90(10):1562-1569.
74. World Health Organization [WHO] Hepatitis C 2002, World Health Organization, Geneva.
75. World Health Organization [WHO] International statistical classification of diseases and related health problems 2007, World Health Organization, Geneva.
76. Wu H.X., Wu J., Wong T., et al. Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998-2004. Scandinavian Journal of Infectious Diseases 2006, 38(6):482-489.
77. Zekry A., Patel K., McHutchison J.G. Treatment of acute hepatitis C infection: More pieces of the puzzle?. Journal of Hepatology 2005, 42(3):293-296.
78. Zou, S., El Saadany, S., Forrester, S., & Giulivi, A. (2001). Estimating the incidence of hepatitis C virus infection in Canada. Paper presented at: Canadian Conference on Epidemiology, Ottawa.